Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
New research has identified the therapeutic potential of a small-molecule inhibitor of the prostaglandin E2 receptor EP4 against pathophysiology and pain in osteoarthritis.
Low copy number of the complement component gene C4A is associated with the presence of autoantibodies and occurrence of systemic autoimmune inflammatory disease.
New research has identified an autoinflammatory syndrome caused by mutations in NEMO-encoding IKBKG, leading to NF-κB activation and type I interferon production.
New research shows that PD1 can be potentiated by freeing up its ligand, PDL1, from binding to CD80, thereby improving symptoms of autoimmune disease in animal models.
New research shows that induction of ferroptosis can deplete synovial fibroblasts that are activated in rheumatoid arthritis, and that co-treatment with a TNF inhibitor enhances this depletion.
proBDNF and its receptor are expressed in antibody-secreting cells in systemic lupus erythematosus, identifying a potential biomarker of disease activity and a therapeutic target.
New research identifies the CD6 ligand ALCAM as a urinary biomarker of lupus nephritis, and shows that CD6 blockade can reduce lupus nephritis disease activity.
In addition to the time since rituximab treatment, new results show that B cell reconstitution is important for response to vaccination in patients with autoimmune rheumatic disease.
In a rabbit model of osteoarthritis, cartilage regeneration was promoted by a biodegradable implant that generates a piezoelectric response during physical exercise.
Combining the diverse expertise of clinical and scientific researchers from across Europe as well as patient representatives and pharmaceutical industry partners, the HIPPOCRATES consortium aims to characterize the molecular pathways underlying psoriatic arthritis in order to improve early diagnosis and precision treatment strategies for the disease.
Results from two phase III trials suggest that the IL-23 inhibitor risankizumab could offer an additional option for the treatment of psoriatic arthritis.
In a multicentre, longitudinal study, researchers have evaluated the association of baseline criteria in patients with Raynaud phenomenon and 5-year progression to systemic sclerosis.
Results from the iFAME-Fertility study indicate that pre-conception paternal inflammatory arthritis is associated with the subsequent risk of miscarriage.
